Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.

Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F.

Dig Liver Dis. 2019 Jul 16. pii: S1590-8658(19)30672-3. doi: 10.1016/j.dld.2019.06.015. [Epub ahead of print]

PMID:
31320302
2.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
3.

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX.

Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29.

4.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
5.

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.

Pastorelli D, Fabricio ASC, Giovanis P, D'Ippolito S, Fiduccia P, Soldà C, Buda A, Sperti C, Bardini R, Da Dalt G, Rainato G, Gion M, Ursini F.

Pharmacol Res. 2018 Jun;132:72-79. doi: 10.1016/j.phrs.2018.03.013. Epub 2018 Mar 31.

PMID:
29614381
6.

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Erratum in: Eur J Cancer. 2018 Sep;100:135-136.

PMID:
28591675
7.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.

World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.

8.

Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.

Giovanis P, Pianezze G, Vincenzi V, Manuppelli C, Boaretto M, Pastorelli D.

Hepat Oncol. 2017 Apr;4(2):39-43. doi: 10.2217/hep-2016-0011. Epub 2017 Sep 8. Review.

9.

Therapeutic management of bone metastasis in prostate cancer: an update.

Zustovich F, Pastorelli D.

Expert Rev Anticancer Ther. 2016 Nov;16(11):1199-1211. doi: 10.1080/14737140.2016.1241148. Epub 2016 Oct 6.

PMID:
27666299
10.

A case of psoriasis pustolosa palmaris induced by cetuximab.

Marinello E, Pastorelli D, Alaibac M.

BMJ Case Rep. 2016 Mar 18;2016. pii: bcr2016214582. doi: 10.1136/bcr-2016-214582.

11.

Mesenteric-Portal Vein Resection during Pancreatectomy for Pancreatic Cancer.

Beltrame V, Gruppo M, Pedrazzoli S, Merigliano S, Pastorelli D, Sperti C.

Gastroenterol Res Pract. 2015;2015:659730. doi: 10.1155/2015/659730. Epub 2015 Nov 1.

12.

Nesidioblastosis coexisting with non-functioning islet cell tumour in an adult.

Valli V, Blandamura S, Pastorelli D, Merigliano S, Sperti C.

Endokrynol Pol. 2015;66(4):356-60. doi: 10.5603/EP.2015.0045.

13.

Outcome of pancreaticoduodenectomy in octogenarians: Single institution's experience and review of the literature.

Beltrame V, Gruppo M, Pastorelli D, Pedrazzoli S, Merigliano S, Sperti C.

J Visc Surg. 2015 Nov;152(5):279-84. doi: 10.1016/j.jviscsurg.2015.06.004. Epub 2015 Jun 24. Review.

PMID:
26117303
14.

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F.

World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281.

15.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
16.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G.

Oncologist. 2015 May;20(5):570. doi: 10.1634/theoncologist.2014-0037erratum. No abstract available.

17.

Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.

Cappetta A, Spano L, Evangelista L, Zovato S, Opocher G, Pastorelli D.

Anticancer Drugs. 2015 Feb;26(2):232-5. doi: 10.1097/CAD.0000000000000169.

PMID:
25243456
18.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G.

Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12. Erratum in: Oncologist. 2015 May;20(5):570.

19.

Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature.

Beltrame V, Gruppo M, Pastorelli D, Pizzi S, Merigliano S, Sperti C.

World J Surg Oncol. 2014 Apr 23;12:105. doi: 10.1186/1477-7819-12-105. Review.

20.

Modelling the rheological properties of sludge during anaerobic digestion in a batch reactor by using electrical measurements.

Dieudé-Fauvel E, Héritier P, Chanet M, Girault R, Pastorelli D, Guibelin E, Baudez JC.

Water Res. 2014 Mar 15;51:104-12. doi: 10.1016/j.watres.2013.12.018. Epub 2013 Dec 21.

PMID:
24419207
21.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

PMID:
24188685
22.

The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience.

Pastorelli D, Locatelli MA, Melotti B, Pisano C, Turano S, Mellino U, Provinciali N, Marchetti P, Dazzi C, Berretta M, Giordano A, Lorusso V.

J Chemother. 2013 Oct;25(5):309-17. doi: 10.1179/1973947813Y.0000000118.

PMID:
24070139
23.

Static and dynamic evaluation of pelvic floor disorders with an open low-field tilting magnet.

Fiaschetti V, Pastorelli D, Squillaci E, Funel V, Rascioni M, Meschini A, Salimbeni C, Sileri P, Franceschilli L, Simonetti G.

Clin Radiol. 2013 Jun;68(6):e293-300. doi: 10.1016/j.crad.2012.11.013. Epub 2013 Mar 26.

PMID:
23541093
24.

Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?

Vitale A, Boccagni P, Kertusha X, Zanus G, D'Amico F, Lodo E, Pastorelli D, Ramirez Morales R, Lombardi G, Senzolo M, Burra P, Cillo U.

Transplant Proc. 2012 Sep;44(7):1989-91. doi: 10.1016/j.transproceed.2012.06.046.

PMID:
22974889
25.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; PEER investigators.

Ann Oncol. 2012 Aug;23(8):1986-92. Epub 2012 Mar 6.

PMID:
22396444
26.

Second-line therapy for refractory renal-cell carcinoma.

Zustovich F, Lombardi G, Nicoletto O, Pastorelli D.

Crit Rev Oncol Hematol. 2012 Jul;83(1):112-22. doi: 10.1016/j.critrevonc.2011.08.008. Epub 2011 Sep 22. Review.

PMID:
21944739
27.

Dynamic MR defecography with an open-configuration, low-field, tilting MR system in patients with pelvic floor disorders.

Fiaschetti V, Squillaci E, Pastorelli D, Rascioni M, Funel V, Salimbeni C, Fanucci E, Simonetti G.

Radiol Med. 2011 Jun;116(4):620-33. doi: 10.1007/s11547-011-0660-2. Epub 2011 Mar 19. English, Italian.

PMID:
21424567
28.

Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.

Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G, Zagonel V.

Crit Rev Oncol Hematol. 2012 Jan;81(1):38-48. doi: 10.1016/j.critrevonc.2010.12.006. Epub 2011 Jan 20. Review.

PMID:
21256046
29.

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Zustovich F, Lombardi G, Pastorelli D, Farina P, Bianco MD, De Zorzi L, Palma MD, Nicoletto O, Zagonel V.

Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230. Review.

30.

Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.

Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma M, Rotilio A, Nicoletto O, Zagonel V.

Anticancer Res. 2010 Dec;30(12):5213-6.

PMID:
21187515
31.

Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results.

Orlacchio A, Bolacchi F, Petrella MC, Pastorelli D, Bazzocchi G, Angelico M, Simonetti G.

Ultrasound Med Biol. 2011 Jan;37(1):1-6. doi: 10.1016/j.ultrasmedbio.2010.10.012.

PMID:
21144954
32.

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.

Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D.

Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.

33.

Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.

Artioli G, Mocellin S, Borgato L, Cappetta A, Bozza F, Zavagno G, Zovato S, Marchet A, Pastorelli D.

Anticancer Res. 2010 Sep;30(9):3817-21. Erratum in: Anticancer Res. 2011 Feb;31(2):751. Grazia, Artioli [corrected to Artioli, Grazia]; Simone, Mocellin [corrected to Mocellin, Simone]; Lucia, Borgato [corrected to Borgato, Lucia]; Alessandro, Cappetta [corrected to Cappetta, Alessandro]; Fernando, Bozza [corrected to Bozza, Fernando]; Giorgi.

PMID:
20944176
34.

Taking decisions on expenditure for high-cost drugs at the regional level: a model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy.

Buja A, Perissinotto E, Compostella A, Tramarin A, Rebba V, Pastorelli D, Grigoletto F, Gallo C, Rausa G, Gregori D.

J Eval Clin Pract. 2011 Apr;17(2):298-303. doi: 10.1111/j.1365-2753.2010.01440.x. Epub 2010 Sep 28.

PMID:
20874838
35.

Vulvar cancer: prognostic factors.

Nicoletto MO, Parenti A, Del Bianco P, Lombardi G, Pedrini L, Pizzi S, Carli P, Della Palma M, Pastorelli D, Corti L, Becagli L.

Anticancer Res. 2010 Jun;30(6):2311-7.

PMID:
20651385
36.

An update on targeted therapy in metastatic renal cell carcinoma.

Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D.

Urol Oncol. 2012 May-Jun;30(3):240-6. doi: 10.1016/j.urolonc.2009.12.018. Epub 2010 Apr 24. Review.

PMID:
20456985
37.

Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.

Pastorelli D, Zustovich F, Faggioni G, Zovato S, Donach M, Nicoletto O, Farina M, Furini L, Ceravolo R, Carli P, Lombardi G.

Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f.

PMID:
19952729
38.

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.

Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U.

Hepatology. 2010 Jan;51(1):165-73. doi: 10.1002/hep.23260.

39.

Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches.

Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D.

Am J Clin Oncol. 2010 Aug;33(4):420-3. doi: 10.1097/COC.0b013e3181aacbbf. Review.

PMID:
19858695
40.

Important role of gemcitabine in the treatment of classic Kaposi's sarcoma.

Zustovich F, Lombardi G, Pastorelli D.

Tumori. 2009 Jul-Aug;95(4):562-3. No abstract available.

PMID:
19856679
41.

A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.

Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D.

Anticancer Res. 2009 Oct;29(10):4275-9.

42.

Important role of thiamine in preventing ifosfamide-induced encephalopathy.

Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D.

J Oncol Pharm Pract. 2010 Jun;16(2):135-6. doi: 10.1177/1078155209342134. Epub 2009 Aug 19. No abstract available.

PMID:
19692431
43.

Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions.

Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A.

Oncology. 2009;76(6):375-86. doi: 10.1159/000215581. Epub 2009 Apr 30. Review.

PMID:
19407470
44.

Gastrointestinal stromal tumors: report of an audit and review of the literature.

Biasco G, Velo D, Angriman I, Astorino M, Baldan A, Baseggio M, Basso U, Battaglia G, Bertin M, Bertorelle R, Bocus P, Brosolo P, Bulzacchi A, Cannizzaro R, Da Dalt GF, Di Battista M, Errante D, Fedrigo M, Frustaci S, Lionetti I, Massani M, Mencarelli R, Montesco MC, Norberto L, Pantaleo MA, Pasquali C, Pastorelli D, Rossi CR, Ruffolo C, Salvagno L, Saponara MS, Vittadello F, Zaccaria F, Zovato S, Farinati F; Section of Oncology of the Italian Society of Gastroenterology; Interdisciplinary GIST Group-G.I.GIST, Veneto Institute of Oncology IOV-IRCCS Azienda Ospedale, University of Padua; GIST Study Group, Bologna University.

Eur J Cancer Prev. 2009 Apr;18(2):106-16. doi: 10.1097/CEJ.0b013e32830c8da8. Review.

PMID:
19337057
45.

New type of asymptomatic congenital portosystemic shunt.

Bazzocchi G, Pastorelli D, Laviani F, Simonetti G.

Clin J Gastroenterol. 2009 Feb;2(1):43-46. doi: 10.1007/s12328-008-0037-9. Epub 2008 Nov 15.

PMID:
26191808
46.

Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature.

Sperti C, Berselli M, Pasquali C, Pastorelli D, Pedrazzoli S.

World J Gastroenterol. 2008 Feb 14;14(6):960-5.

47.

Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience.

Orlacchio A, Bazzocchi G, Pastorelli D, Bolacchi F, Angelico M, Almerighi C, Masala S, Simonetti G.

Cardiovasc Intervent Radiol. 2008 May-Jun;31(3):587-94. doi: 10.1007/s00270-008-9293-9. Epub 2008 Jan 31.

PMID:
18236104
48.

A phase II study of gemcitabine at fixed infusion rate of 10 mg/m2/min with or without immunotherapy in advanced renal cancer.

Zustovich F, Cartei G, Pastorelli D, Nicoletto O, Gottardo F, De Zorzi L, Dal Bianco M.

Anticancer Res. 2007 Nov-Dec;27(6C):4461-4.

49.

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors.

Zustovich F, Cartei G, Ceravolo R, Zovato S, Della Puppa A, Pastorelli D, Mattiazzi M, Bertorelle R, Gardiman MP.

Anticancer Res. 2007 Mar-Apr;27(2):1019-24.

50.

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.

Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini S, Salmaso F, Mattiazzi M, Sanavio C, Farinati F, Zanus G, Cillo U.

Ann Oncol. 2006 May;17 Suppl 5:v153-7. Review.

PMID:
16807446

Supplemental Content

Loading ...
Support Center